A
Alan R. Giles
Researcher at Queen's University
Publications - 71
Citations - 2737
Alan R. Giles is an academic researcher from Queen's University. The author has contributed to research in topics: Thrombin & Von Willebrand factor. The author has an hindex of 29, co-authored 71 publications receiving 2657 citations. Previous affiliations of Alan R. Giles include Organon International.
Papers
More filters
Journal ArticleDOI
Efficacy of Auxiliary Partial Orthotopic Liver Transplantation for Cure of Hemophilia in a Canine Hemophilia a Model
Saiho Ko,Ichiro Tanaka,Hideki Kanokogi,Hiromichi Kanehiro,Junji Okayama,Jun-ichi Ori,Midori Shima,Akira Yoshioka,Alan R. Giles,Yoshiyuki Nakajima +9 more
TL;DR: A canine APOLT model was successfully established as evidenced by sustained production of factor VIII in a hemophilia recipient, suggesting the clinical feasibility and efficacy of APOLt for metabolic liver diseases.
Journal ArticleDOI
Aortic endothelial cell von Willebrand factor content, and circulating plasminogen activator inhibitor-1 are increased, but expression of endothelial leukocyte adhesion molecules is unchanged in insulin-dependent diabetic BB rats.
José C.O Ribau,John A. Samis,Yotis A. Senis,Donald H. Maurice,Alan R. Giles,Marnie DeReske,P. Marlene Absher,Mark W.C. Hatton,Mary Richardson +8 more
TL;DR: Endothelial alterations in BB rats associated with diabetes, together with the raised plasma PAI-1 levels, promote the thrombogenic potential of the vessel wall, and are consistent with an increased risk for vascular disease.
Journal ArticleDOI
A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred
S. A. M. Taylor,David Lillicrap,Victor S. Blanchette,Alan R. Giles,J. J. A. Holden,Bradley N. White +5 more
TL;DR: A hemophilia B kindred in which the proband has a complete deletion of the factor IX gene extending a minimum of 80 kilobase pairs (kb) 3′ of the gene is reported, with severe factor IX deficiency with no detectable circulating factor IX protein.
Journal ArticleDOI
Activated thrombin‐activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation
TL;DR: A new assay for measuring functional TAFIa in plasma is described, based on the ability of TAFia to catalyze the release of fluorescent plasminogen bound to soluble high molecular weight fibrin degradation products that are covalently attached to a fluorescence quencher.